Kornimate/medical-research-clean huggingface dataset:
epoch chemotherapy +/- il-12 for previously untreated and epoch plus rituximab for previously treated patients with aids-associated lymphoma

Conditions: AIDS Related Lymphoma; AIDS-Associated Lymphoma

Summary: the prognosis of aids-related non-hodgkin's lymphoma is poor, especially in the relapsed setting. there is no standard treatment, and the few small studies that have been conducted have reported dismal outcomes. the purpose of this study is to pilot the use of epoch plus rituximab in previously treated aids-related lymphoma. clinical endpoints of the study include toxicity and response. progression-free and overall survival will be measured. tumors will be evaluated for p53 mutations, p-16, bcl-2 expression, tumor proliferation, c-myc and ebv when possible.

the prognosis of aids-related non-hodgkin's lymphoma is poor, especially in the relapsed setting. there is no standard treatment, and the few small studies that have been conducted have reported dismal outcomes. the purpose of this study is to pilot the use of epoch plus rituximab in previously treated aids-related lymphoma. clinical endpoints of the study include toxicity and response. progression-free and overall survival will be measured. tumors will be evaluated for p53 mutations, p-16, bcl-2 expression, tumor proliferation, c-myc and ebv when possible.

Eligibility criteria:
* inclusion criteria: aggressive cd20 + nhl confirmed by pathology, dcs. hiv + serology. all stages (i-iv) of disease. nhl previously treated with up to two chemotherapy regimens and evaluable disease. age greater than or equal to 18 years. laboratory test: (abnormalities are allowed if due to organ involvement by lymphoma). creatinine less than or equal to 1.7. bilirubin must be less than 2.0 mg/dl, or total bilirubin less than or equal to 3.7 mg/dl with direct fraction less than or equal to 0.2 mg/dl and indirect fraction of less than or equal 3.5 mg/dl in patients for whom these abnormalities are felt to be due to protease inhibitor therapy. ast and alt less than or equal to 3 times uln (ast and alt less than or equal to 6 times uln for patients on hyperalimentation for whom these abnormalities are felt to be due to the hyperalimentation). anc greater than or equal 1000/mm(3). platelets must be greater than or equal to 75,000/mm(3) (patients with itp platelets greater than or equal to 30,000/mm(3). signed informed consent and durable power of attorney. exclusion criteria: pregnancy or nursing. history of clinical heart failure or symptomatic ischemic heart disease. serious underlying medical condition or infection other than hiv that would contraindicate epoch. concurrent anti-retroviral therapy during epoch therapy. primary cns lymphoma.

Keywords: lymphomagenesis molecular markers of drug resistance refractory, progressive, or relapsed hiv + nhl aids-related nhl
social exergaming for healthy weight in adolescent girls

Conditions: Obesity and Physical Inactivity in Adolescents

Summary: the purpose is to evaluate the feasibility of a 12-week exergaming dance program for adolescent girls. this study combines dancing, video games, and a full body work-out to test if video games can increase physical activity and promote healthy weight in adolescent girls. we hypothesize that girls who play the dance exergames, versus those in the control group, will lose weight, decrease body fat and visceral fat, improve cardiovascular health, increase physical activity, and improve psychosocial health including self-confidence and quality of life.

klub kinect will last about 14 weeks for each participant. the program begins with a 3.5 hour clinic visit, the intervention lasts for 12 weeks, and the participant comes in for a final 3.5 hour clinic visit.

Eligibility criteria:
inclusion criteria: * age 14-18 years old * female * postmenarchal * bmi percentile equal to or greater than 85th on the u.s. centers for disease control and prevention growth chart * speak, understand, read, and write english * willing to accept randomization exclusion criteria: * pregnant * hospitalization for mental illness within the past 5 years. * since the focus herein is on ambulatory activities, participants who use wheelchairs or other impairments that prevent normal ambulation will be excluded * indication of cardiac abnormality on an electrocardiogram that requires referral to a cardiologist * previous history of, or clinical symptoms or signs of, cardiovascular disease, stroke or transient ischemic attacks, chest pain, unusual dyspnea during physical activity/exercise, severe ankle edema, or intermittent claudication. * previous history of musculoskeletal injuries or problems causing severe pain during physical activity or exercise which interferes with daily activities. * participant has a pacemaker or other implanted medical device (including metal joint replacements). * participant is unable to complete all baseline testing (one session) within 1 month prior to the beginning of the intervention * medical problems, including epileptic seizures, that prevent video game play * family history of epileptic seizures * unable to make the commitment of coming to pennington biomedical research center for 3 weekly gaming sessions for 12 weeks

Keywords: physical activity sedentary behavior video games exergames
the study focuses on the release of the iliolumbar ligament using a pumped technique, addressing its tightness caused by excessive anterior pelvic tilt during pregnancy. this condition often results in low back pain and mechanical dysfunction of the lumbar and sacroiliac regions.

Conditions: Low Back Pain

Summary: the iliolumbar ligament, one of the sacroiliac ligaments, has been identified in recent research as a contributor to low back pain when tight. during pregnancy, hormonal changes and postural changes can cause this ligament to tighten, leading to pain. releasing the iliolumbar ligament can reduce low back pain and restore normal mechanical function.

group a (control group) it will be consisted of postnatal women and will be treated by hot packs for 20 minutes three times per week for 8 weeks. group b (study group) the participant will treated by hot packs for 20 min in additional to pumping technique for iliolumbar ligament release for 30 min. 3 times per week for 8 weeks.

Eligibility criteria:
inclusion criteria: 1- the women are delivery within 3 months. 3- their bmi must be less than 30 kg\\m 2 . 4- its included primipara or multipara. 5- its included be normal vaginal labor delivery or caesarian section. exclusion criteria: 1. clinical diagnosis by lumbar disc prolapse. 2. clinical diagnosis by lumbar spondylolysis and spondlysis. 3. clinical diagnosis by back trauma or fracture. 4. clinical diagnosis by lumbar canal stenosis. 5. clinical diagnosis by rheumatoid arthritis. 6. clinical diagnosis by malignancy. 7. clinical diagnosis by any deformity for low limb. 8. clinical diagnosis by scoliosis. 9. taking analgesic drugs. 10. clinical diagnosis by deep vein thrombosis

Keywords: low back pain lumbar and sacroiliac pain iliolumbar ligament disorder
intrauterine microbiota during ivf in patients affected with isthmocele.

Conditions: Endometrial Diseases

Summary: to evaluate the endometrial and isthmic microbiota in patients with isthmocele after c-section, and if this microbiota is similar or not with better reproductive outcomes.

a total of 45 subjects undergoing in vitro fertilization treatment. fifteen patients without isthmocele will be included in the control group and 30 patients affected with isthmocele in the other group, divided in 2 subgroups: 15 with 1 previous c-section, and 15 with 2 or more previous c-section. paired samples of endometrial fluid (ef) and isthmic fluid (if) will be obtained simultaneously the day of egg retrieval. patients will follow a protocol for all-freezing embryos or oocytes.

Eligibility criteria:
inclusion criteria: 1. patients with isthmocele: * patients performing ivf treatment with a planned cycle segmentation and consecutive frozen embryo transfer on a hormone replacement therapy (hrt) cycle or natural cycle. * age between 18 - 45 years all (both inclusive). * one or multiple c-sections. * isthmocele present during tv scan. * bmi: 18,5 - 35 kg / m2 (both inclusive). 2. patients without isthmocele: * patients performing ivf treatment with planned cycle segmentation and who would have embryo transfer with frozen embryos under hormone replacement therapy. * no isthmocele present during transvaginal ultrasound. * bmi: 18,5 - 30 kg / m2 (both inclusive). exclusion criteria: * age \ 45 years old. * previous or active endometritis. * patients who are iud carriers for the last 3 months. * patients who have taken prescribed antibiotics in the last 3 months previous to sample collection.
snodgrass versus grafted snodgrass repair in narrow urethral plate in distal penile hypospadias

Conditions: Hypospadias

Summary: we aime to compare between snodgrass and grafted snodgrass repair in the outcome in distal penile hypospadias with urethral plate less than 8mm

the main goal for hypospadias repair is to achieve both cosmetic and functional normality. several surgical techniques for hypospadias repair have been developed that depend on the site of the urethral meatus in children the effect of the urethral plate characteristics on the surgical outcome of snodgrass repair has been studied in many series. some documented that urethral plate width has a significant impact on the complication rates holland and smith reported a high complication rate in snodgrass repair with a urethral plate width of less than 8 mm 7 the augmentation of the urethral plate either with inlay graft (digu, snodgraft, or g-tip), onlay preputial flap, or other flaps carries a better outcome than the original tip in many studies others denied any effect of the narrow urethral plate on the success rate we aim in this study to determine which is better in narrow urethral plate in distal penile hypospadias, as regarding surgical and cosmetic outcomes; snodgrass or combined inner preputial graft with snodgrass

Eligibility criteria:
inclusion criteria: children age: \> 6m up to 16y * distal penile hypospadias(distal shaft,coronal,subcoronal ) * mid penile hypospadias with mild chordae les 30 degree * urethral plate \<8 mm in maximum transverse diameter before the midline urethral plate incision .primary non-circumcised cases of hypospadias exclusion criteria: * proximal and mid penile hypospadias with marked chordae * previous hypospadias repair
optimizing outcomes of treatment-resistant depression in older adults

Conditions: Treatment Resistant Depression; Major Depressive Disorder; Treatment-Refractory Depression; Late Life Depression; Geriatric Depression

Summary: the purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (trd).

older adult participants with treatment-resistant depression will be randomly assigned to a step 1 medication strategy. * adding aripiprazole to current antidepressant medication * adding bupropion to current antidepressant medication * replacing current antidepressant medication with bupropion if depression is not relieved at the end of 10 weeks, or if participants do not qualify for step 1, participants will be randomly assigned to a step 2 medication strategy: * adding lithium to current antidepressant medication * replacing current antidepressant medication with nortriptyline all medication strategies will be offered in collaboration with participants' own physicians with the the research team providing support and guidance. after treatment in step 1 and/or step 2, participants will enter the continuation phase to assess long term follow-up outcomes for 12 months. participants in this clinical trial will also be asked to participate in an additional study to gather imaging and biomarker data.

Eligibility criteria:
inclusion criteria: * men and women aged 60 and older * current major depressive disorder (mdd) * failure to respond adequately to two or more antidepressant treatment trials of recommended dose and length * patient health questionnaire-9 (phq-9) score of 10 or higher exclusion criteria: * inability to provide informed consent * dementia * lifetime diagnosis of bipolar i or ii disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms * high risk for suicide and unable to be managed safely in the clinical trial * contraindication to proposed study medications, as determined by study physician including history of intolerance or non-response to proposed medications. * non-correctable, clinically significant sensory impairment interfering with participation * unstable medical illness, including delirium, uncontrolled diabetes mellitus, hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that are not under medical management. * moderate to severe substance or alcohol use disorder

Keywords: comparative effectiveness research pragmatic clinical trials patient-centered outcomes research
hemostatic profiles of endocrine therapies for breast cancer

Conditions: Breast Neoplasms; Venous Thromboembolism

Summary: the aim of this prospective cohort study is to evaluate the modifications of the biological hemostatic profile associated with the use of endocrine therapy in women with breast cancer (tamoxifen or aromatase inhibitors).

in this cohort study, women with breast cancer and an indication for endocrine therapy will be prospectively enrolled. at the 1st visit (before the start of endocrine therapy (tamoxifen or aromatase inhibitor)) and at the 2nd visit (at \~3 months after the start of treatment), demographical / clinical data and blood samples will be collected. we will evaluate the hemostatic biological profiles associated with the use of endocrine therapy by comparing hemostatic biomarkers before and during its use.

Eligibility criteria:
inclusion criteria: adult women with a diagnosis of non-metastatic breast cancer and an indication for adjuvant endocrine therapy exclusion criteria: * lack of consent * planned chemotherapy * personal history of venous thromboembolism * ongoing anticoagulant treatment

Keywords: tamoxifen aromatase inhibitors breast cancer venous thromboembolism
adaptation in lower extremity after 3 running days, with a group trained by eccentric overload

Conditions: Sports Injuries

Summary: this study evaluates the changes in muscles and tendons in the lower limb after an intervention of fatigue during 3 consecutive days between trained or not healthy subjects. one of the 2 groups received training by eccentric overload previously.

changes in muscle and tendon tissues, due to exercise, could determine in the future the possibility of an injury. understand the changes in the mechanical tissues is a key tool for prevention. the evaluation of the thickness and area in tendons, the existence of new vessels within the tendon, muscle pennation angle or thermography are tools that have been widely used to detect these changes. running is one of the activities that can cause more muscle-tendon injuries, specially overuse injuries. however, the eccentric exercise suggest to make some adaptations in different tissues that may be beneficial to prevent damage after exercise.

Eligibility criteria:
inclusion criteria: * healthy subjects that performs any sport usually * subjects that never have made eccentric training will be included. * subjects must be willing to perform the procedure * sign informed consent exclusion criteria: * subjects enrolled with lower limb pathology in last 6 months * subjects that don´t complete all the procedure will be excluded.

Keywords: eccentric running muscle tendon ultrasound thermography
randomized, controlled study evaluating cere-110 in subjects with mild to moderate alzheimer's disease

Conditions: Alzheimer's Disease

Summary: the purpose of this study is to evaluate the potential benefits of cere-110 in the treatment of alzheimer's disease. cere-110 is an experimental drug that is designed to help nerve cells in the brain function better. cere-110 uses a virus to transfer a gene that makes nerve growth factor (ngf), a protein that may make nerve cells in the brain healthier and protect them from dying. the virus used in cere-110 does not cause disease in people. cere-110 has been carefully studied in laboratory animals and is in the early stages of being tested in people. fifty patients with mild to moderate alzheimer's disease will participate in this study. half of the study subjects will have cere-110 injected into the brain during a surgical procedure, while the other half will undergo a "placebo" surgery where no medication will be injected. all study participants will be followed for at least two years after surgery.


Eligibility criteria:
inclusion criteria: * diagnosis of mild to moderate alzheimer's disease * approved medications for alzheimer's disease may be taken if the dose has been stable for 3 months * a study partner who can attend all study visits * good general health * medically able to undergo neurosurgery exclusion criteria: * significant neurological disease other than alzheimer's disease * significant depression or other psychiatric disorder * unstable medical conditions

Keywords: alzheimer's disease dementia memory loss cognitive impairment nerve growth factor ngf neurotrophic factors gene therapy
choice of palliative procedures for pulmonary atresia with ventricular septal defect patients

Conditions: Pulmonary Atresia With Ventricular Septal Defect; Tetralogy of Fallot With Pulmonary Atresia

Summary: the aim is to compare effective growth true hypoplastic pulmonary arteries using right ventricle outflow tract reconstruction by femoral allogenic vein valve conduit and systemic-to-pulmonary artery shunts (modified blalock-taussig shunt)

the use of femoral allogenic vein valve conduit for right ventricle outflow tract reconstruction is good alternative systemic-to-pulmonary artery shunts (modified blalock-taussig shunt). main advantages is straight, symmetrical, pulsating, systolic blood flow in hypoplastic pulmonary artery, which stimulate growth and prepares for a radical repair. taking into account the absence randomized studies in this area of medicine, providing investigation evaluating parameters of safety for both methodics is very actual.

Eligibility criteria:
inclusion criteria patients who met the following criteria were included: * patients with pa-vsd type a and b (by tchervenkov) scheduled for palliative surgery * age less than one year * confluent pulmonary artery * nakata index ≤ 120 mm2/m2. exclusion criteria patients who met any of the following criteria were excluded: * discordant atrioventricular and/or discordant ventriculo-arterial connections * concomitant pathology (pneumonia, brain damage, or enterocolitis) * genetic syndromes (digeorge, alagille, vacter, charge) * scheduled mapca unifocalisation * anomalous coronary arteries * other surgical approaches (complete primary repair, primary unification of pulmonary blood flow, stenting rvot, or patent ductus arteriosus, radiofrequency pulmonary valve perforation).

Keywords: femoral allogenic vein valve conduit rehabilitation of native pulmonary arteries
safety and efficacy study of ceftaroline versus a comparator in pediatric subjects with community acquired bacterial pneumonia (cabp)

Conditions: Infections; Community Acquired Pneumonia

Summary: this is a study of safety and effectiveness of ceftaroline fosamil in children with community acquired bacterial pneumonia receiving antibiotic therapy in the hospital.

to evaluate safety, effectiveness, pharmacokinetics and tolerance of ceftaroline fosamil in children who are initially hospitalized with community acquired bacterial pneumonia (cabp)

Eligibility criteria:
inclusion criteria: * male or female, 2 months to \< 18 years old. * presence of cabp requiring hospitalization and iv antibacterial therapy exclusion criteria: * documented history of any hypersensitivity of allergic reaction to any β-lactam antimicrobial. * confirmed or suspected infection with a pathogen known to be resistant to ceftriaxone. * confirmed or suspected respiratory tract infection attributed to sources other than cabp pathogens. * non-infectious causes of pulmonary infiltrates.

Keywords: infections pediatrics teflaro cephalosporin
autologous atrial appendage derived cells in the treatment of heart failure

Conditions: Heart Failure

Summary: this study aims to evaluate the safety and clinical feasibility of epicardially delivered autologous atrial appendage micrografts in the treatment of heart failure. the micrografts consisting atrial-derived cells and their extracellular matrix, are placed on an infarction scar during cabg surgery.

the atrial appendages are a tissue reservoir for cardiomyocyte stem and precursor cells. during coronary artery bypass graft (cabg) surgery part of the right atrial appendage can be excised upon insertion of the right atrial cannula of the heart-lung machine. this study aims to address the surgical feasibility and patient safety of epicardially delivered atrial appendage micrografts during cabg surgery. autologous cardiac cells are harvested from right atrial appendage during cabg of six patients. micrografts consisting atrial appendage-derived cells (aadcs) and their extracellular matrix (ecm) of the atrial appendage are mechanically processed. the cells are placed on a tissue-engineered sheet with fibrin gel and tissue clue and further delivered epicardially on top of a infarction scar. parameters including echocardiography reflecting cardiac insufficiency are studied pre- and post-operatively as well as at three and six months of the follow-up. cardiac functional magnetic resonance imaging is performed preoperatively and at six-months follow-up. 20 patients will be recruited to serve as a control group. they are scheduled for elective cabg and are treated according to the normal hospital protocol, without the ecm sheet.

Eligibility criteria:
inclusion criteria: * informed consent obtained * left ventricular ejection fraction (lvef) between ≤50% and ≥15% * new york heart association (nyha) class ii-iv heart failure symptoms exclusion criteria: * heart failure due to left ventricular outflow tract obstruction * history of life-threatening and possibly repeating ventricular arrhythmias or resuscitation, or an implantable cardioverter-defibrillator * stroke or other disabling condition within 3 months before screening * severe valve disease or scheduled valve surgery * renal dysfunction (gfr \<84 ml/min/1.73m) * other disease limiting life expectancy * contraindications for coronary angiogram or mri * participation in some other clinical trial

Keywords: autologous micrografts heart failure coronary artery bypass surgery cell therapy atrial appendage epicardial cell delivery